PURE Bioscience to Present at 6th Annual LD MICRO Conference
PURE Bioscience to Present at 6th Annual LD MICRO Conference
SAN DIEGO, CA--(Marketwired - Nov 25, 2013) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Peter C. Wulff, CFO & COO, will present at the Sixth Annual LD MICRO Conference on Thursday, December 5th, at 1:00 PST, at the Luxe Hotel Sunset Boulevard in Los Angeles.
Mr. Wulff will discuss the Company's outlook and the progress of the efforts of the new management team to establish PURE's SDC technology as a novel and proprietary food safety solution. The presentation will be webcast live and slides may be accessed on the Company's website, http://www.purebio.com/about/investor_relations. The presentation will be archived for 90 days.
About LD MICRO
LD MICRO (http://www.ldmicro.com) is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. It is a non-registered investment advisor. To learn more, please call 408-457-1042 or visit http://www.ldmicro.com
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contacts:
Tom Hemingway
Redwood Investment Group
714-978-4425
Email Contact
Terri MacInnis
Director of IR
Bibicoff + MacInnis, Inc.
818-379-8500
Email Contact
Company Contact:
Peter C. Wulff
CFO & COO
PURE Bioscience, Inc.
619-596-8600 ext.111
Email Contact
PURE Bioscience to Present at 6th Annual LD MICRO Conference
SAN DIEGO, CA--(Marketwired - Nov 25, 2013) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Peter C. Wulff, CFO & COO, will present at the Sixth Annual LD MICRO Conference on Thursday, December 5th, at 1:00 PST, at the Luxe Hotel Sunset Boulevard in Los Angeles.
Mr. Wulff will discuss the Company's outlook and the progress of the efforts of the new management team to establish PURE's SDC technology as a novel and proprietary food safety solution. The presentation will be webcast live and slides may be accessed on the Company's website, http://www.purebio.com/about/investor_relations. The presentation will be archived for 90 days.
About LD MICRO
LD MICRO (http://www.ldmicro.com) is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. It is a non-registered investment advisor. To learn more, please call 408-457-1042 or visit http://www.ldmicro.com
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contacts:
Tom Hemingway
Redwood Investment Group
714-978-4425
Email Contact
Terri MacInnis
Director of IR
Bibicoff + MacInnis, Inc.
818-379-8500
Email Contact
Company Contact:
Peter C. Wulff
CFO & COO
PURE Bioscience, Inc.
619-596-8600 ext.111
Email Contact
